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Abstract—COVID-19 is a major emerging disease that affects any certain condition. However, a recent report suggests the 
occurrence of hyperglycemia without any present diabetes in COVID-19 patients. This study aimed to systematically review recent 
evidence on hyperglycemia in COVID-19 patients. Literature research was done using four search engines, consist of Google 
Scholar, PubMed, ScienceDirect, and ProQuest, and limited to English manuscript only and published from February 2020 to 
September 2020. SARS-CoV-2 could damage the pancreas by causing the destruction of the β-cell structure that leads to 
impairment of glucose metabolism and worsen pre-existing diabetes or determine the appearance of hyperglycemia in non-
diabetes. Inflammation also plays a major important role in hyperglycemia related to COVID-19.  Hyperglycemia increased the 
vulnerability of the lung, by promoting and facilitating the entry of the SARS-CoV-2 into the host cells, and decreasing lung function. 
Moreover, the mortality and morbidity rate conceivable increased due to hyperglycemia. The presence of high glucose levels is 
linked with the progression of COVID-19 severity. Thus, the glucose level should be concerned, either in a patient with present 
diabetes or without any presence of diabetes. Examination and monitoring of glucose levels might be a useful tool to prevent the 
seriousness of COVID-19. 
 
Keywords: diabetes mellitus, SARS-CoV-2, high glucose level, pulmonary infection 
 
Abstrak—COVID-19 adalah penyakit yang muncul yang mempengaruhi kondisi  tertentu.Namun, sebuah laporan baru-baru ini 
menunjukkan terjadinya hiperglikemia tanpa adanya diabetes pada pasien COVID-19. Penelitian ini bertujuan untuk meninjau 
secara sistematis bukti terbaru tentang hiperglikemia pada pasien COVID-19. Penelitian literatur dilakukan dengan menggunakan 
empat mesin pencari, yaitu Google Scholar, PubMed, ScienceDirect, dan ProQuest, dan terbatas hanya pada manuskrip berbahasa 
Inggris dan diterbitkan dari Februari 2020 hingga September 2020. SARS-CoV-2 dapat merusak pankreas dengan menyebabkan 
kerusakan pada pankreas. struktur sel β yang menyebabkan gangguan metabolisme glukosa dan memperburuk diabetes yang 
sudah ada sebelumnya atau menentukan munculnya hiperglikemia pada kelompok non-diabetes. Peradangan juga memainkan 
peran penting utama dalam hiperglikemia terkait COVID-19. Hiperglikemia meningkatkan kerentanan paru-paru, dengan 
mendorong dan memfasilitasi masuknya SARS-CoV-2 ke dalam sel inang, dan menurunkan fungsi paru-paru. Selain itu, angka 
mortalitas dan morbiditas yang diperkirakan meningkat karena hiperglikemia. Adanya kadar glukosa yang tinggi dikaitkan dengan 
perkembangan keparahan COVID-19. Dengan demikian, kadar glukosa harus diperhatikan, baik pada pasien dengan diabetes saat 
ini atau tanpa adanya diabetes. Pemeriksaan dan pemantauan kadar glukosa mungkin menjadi alat yang berguna untuk mencegah 
derajat keparahan COVID-19. 
 
Kata kunci: diabetes mellitus, SARS-CoV-2, peningkatan kadar glukosa, infeksi paru 
 
INTRODUCTION 
The Coronavirus Disease 2019 (COVID-19) pandemic is not over and the solution has 
yet to be found. It is more than a health crisis, COVID-19 affected many aspects in life. To date, 
more than 1.000.000 deaths is caused by COVID-19 [1]. Compared to other countries in South 
East Asia, Indonesia has higher mortality [2]. Several factors contribute to the severity and 
mortality of COVID-19. Comorbidities has been known to increase the severity of COVID-19 
and diabetes is included [3]. It is also known that diabetic patients tend to have high blood 
glucose level or hyperglycemia [4]. However, a recent report suggests the occurrence of 
hyperglycemia without any present diabetes in COVID-19 patients [5–8].  Some studies suggest 
hyperglycemic condition could be a predictor of mortality in COVID-19 patients [4,9–14]. The 
systematic review was conducted to analyze the occurrence of hyperglycemia in COVID-19 
patients with diabetes and without present diabetes. 
 
METHODS 
 Comprehensive literature searches were conducted using four electronic databases, 
PubMed, ProQuest, Science Direct, and Google Scholar. A limitation is set on literature 
searches using only published journals from February 2020 to September 2020 and English-
Original Research 
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language manuscripts. Boolean logic was used to combine search terms as seen in the 
following Table 1. Literature searches in each database were conducted to find journals that 
contain information about hyperglycemia-associated COVID-19. Full text articles with cohort 
studies containing hyperglycemia-associated COVID-19 were obtained.  
 Afterwards, screening on journals abstract and title were done using inclusion criteria 
according to the following PICO, P: confirmed COVID-19 patients, I: diabetes and non-diabetes, 
C: not available, O: hyperglycemia. While the exclusion criteria were those journals contained a 
restricted discussion about diabetes as a comorbidity in COVID-19 patients without any further 
data about non-diabetes and those only discussed COVID-19 with or without diabetes, yet not 
associating hyperglycemia. Critical appraisals were conducted using Oxford’s Centre for 
Evidence-Based Medicine worksheets [15].  
 
Table 1 




 A total of 704 published papers about hyperglycemia in COVID-19 patients with 
diabetes or without present diabetes from four electronic databases were identified 
and 692 were excluded. Eight articles were analyzed and discussed, the critical 
appraisals can be seen in Table 2 below.  Each study compared high blood sugar levels 
or hyperglycemia in diabetic patients group and non-diabetic patients group. The 
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 









Database Keywords Results 
PubMed “covid-19” or “sars-cov-2” and “hyperglycemia” 
and “diabetes” 
101 
ProQuest “covid-19” and “hyperglycemia” and “diabetes” 
and “without diabetes” or “non diabetes” 
365 
Science Direct covid-19 or sars-cov-2 and diabetes and without 
diabetes and hyperglycemia 
172 
Google Scholar “covid-19” and “hyperglycemia” and “diabetes” 
and “without diabetes” or “non diabetes” 
66 
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Table 2  
Critical Appraisal Of The Studies Included In The Systematic Review  
First author and 
year 
Study size and 
settings 
Study design Study period Outcomes 
Mamtani, 20205 403 patients admitted to 
John H Stroger Chicago 
Obervational 
cohort 
March 15, 2020 







Admission to ICU 
DM(+)HG(+) 32.4% 





DM(+) HG(-) 10.0% 
DM(-)HG(+) 32.5% 
DM(-)HG(-) 0.6% 
DM = history of diabetes 
HG = blood glucose ≥7.78 mmol/L 
Wu, 202010 2,041 patients from two 





2019 to March 
15, 2020 
Critical condition 
Normal initial glucose 33.7% 
Hyperglycemia initial glucose 66.3% 
Zhu, 202011 293 patients from five 




January 17 to 
February 22, 
2020 
Severe or critical case 
FPG <7.05 mmol/L 32.8% 
FPG ≥7.05 mmol/L 67.2% 




February 8 to 
March 21, 2020 
Mortality 
9.5% in No diabetes & FPG < 7.0 
mmol/L 
14.3% in No diabetes & FPG ≥ 7.0 
mmol/L 
21.3% in Diabetes & FPG ≥ 7.0 
mmol/L 
Composite outcomes 
10.7% in No diabetes & FPG < 7.0 
mmol/L 
38.1% in No diabetes & FPG ≥ 7.0 
mmol/L 
27.9% in Diabetes & FPG ≥ 7.0 
mmol/L 




February 4 to 
March 10, 2020 
Hyperglycemia 
61.7% in diabetes 
38.3% in non-diabetes 
 
28-day mortality: 
54.8% in diabetes 
36.8% in non-diabetes 
Liu, 20204 255 patients admitted to 
Tongji Hospital, China 
Retrospective 
cohort 




FPG >7.0 mmol/L 85.4% 
FPG ≤7.0 mmol/L 14.6% 
Carrasco, 202013 11,312 patients in 109 
hospitals in Spain 
Retrospective 
cohort 
March 1 to May 
31, 2020 
Mortality 
15.7% in Admission BG <140 mg/dl 
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33.0% in Admission BG 140 - 180 
mg/dl 
41.1% in Admission BG >180 mg/dl 
Mechanical ventilation 
9.0% in Admission BG <140 mg/dl 
14.3% in Admission BG 140 - 180 
mg/dl 
16.1% in Admission BG >180 mg/dl 
ICU admission 
7.5% in Admission BG <140 mg/dl 
10.6% in Admission BG 140 - 180 
mg/dl 
11.4% in Admission BG >180 mg/dl 
Composited endpoint 
21.7% in Admission BG <140 mg/dl 
40% in Admission BG 140 - 180 mg/dl 
48.6% in Admission BG >180 mg/dl 
Coppelli, 202014 271 patients admitted to 




March 20 to 
April 30, 2020 
In-hospital mortality 
16.8%% in Normoglycemia 
39.4% in Hyperglycemia 
28.6% in Known diabetes 
Need for mechanical ventilation 
11.4% in Normoglycemia 
33.3% in Hyperglycemia 
12.5% in Known diabetes 
Admission to ICU 
24.2% in Normoglycemia 
45.4% in Hyperglycemia 
25.0% in Known diabetes 
Acute respiratory distress syndrome 
32.9% in Normoglycemia 
59.1% in Hyperglycemia 
64.3% in Known diabetes 
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Hyperglycemia in COVID-19 
 Hyperglycemia is a condition of blood glucose greater than 100 mg/dl while fasting (8-
12 hours) or 200 mg/dl randomly. This condition occur when body when body has a little 
insulin or can’t regulate insulin properly. It has been known that hyperglycemia is associated 
with Diabetes. Nevertheless, hyperglycemia can also be found in several condition such as 
stress from illness, such as infection. COVID-19 is a highly contagious disease and has still 
become a major health problem. The mechanism of infection, therapies, and complications 
caused by COVID-19 is still being studied. Severe Acute Respiratory Syndrome Coronavirus 2 
(SARS-CoV-2) infected cell host through S-Glycoprotein structure that binds Angiotensin 
Converting Enzyme 2 (ACE-2) receptor [6,7]. 
  Hyperglycemia in COVID-19 has several mechanisms. The major action can be divided 
into two subdivided. First, there was a direct mechanism via β cells impairment from the virus 
itself. Secondly, an indirect mechanism was found via the impact of pro-inflammatory 
cytokines, acute stress factors, or a history of glucocorticoid therapy usage.5 SARS-CoV-2 could 
damage pancreatic β cells by binding to ACE-2 receptor, hence insulin secretion is impaired. As 
a consequence, blood sugar level will increase and worsen the diabetes condition or induce 
hyperglycemia in patients without prior diabetes. This condition causes glycation of 
immunoglobulin, thus impair the antibodies function, weaken the immune systems, and 
elevation of HbA1c level. Furthermore, pancreatic beta cells impairment may worsen and 
insulin resistance occurs [6]. ACE-2 may also be glycosylated aberrantly, enhancing cellular 
intrusion of SARS-CoV2 and increase the severity of the disease [6,8,10,15,16]. 
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  SARS-CoV-2 may affect the innate immune system by downregulating and shedding 
virus-induced ACE-2, thus stimulate abundant proinflammatory cytokines release in hosts cell 
resulting in cytokine storm [5,8]. Structural and functional damage in endothelial cell occurs in 
this condition leading to impairment in insulin secretion and pancreatic beta cell causing 
hyperglycemia. Meta-analyses studies by Lee et al9 and Sachdeva et al [8] showed that host 
immune response dysregulation which cause cytokine production impairment (e.g. IL-6) will 
induce or worsen insulin resistance and disrupt the insulin secretion.  Zhou et al [6] and 
Mamtani et al [5] in their studies showed that elevation of proinflammatory cytokines in 
circulation, such as CRP, IL-6, Interferon Gamma, and Tumor Necrosis Factor Alpha occured in 
hyperglycemic patients either with diabetes or without diabetes. Sachdeva et al [8] found that 
IL-6 level decreased after the hyperglycemia was treated. Another finding in a study conducted 
by Zhou et al [6] shows a low level of CD3+ and CD4+/CD8+ ratio in hyperglycemic patients 
with and without prior diabetes indicated immune system impairment process. This led to 
surge mechanism of activated-NK cells, proinflammatory cytokine production, reducing T-
helper associated chemokine receptors, and disrupting T cell proliferation in initial stage of 
infection, thus worsen patient condition. Lee et al also stated that hyperglycemia in COVID-19 
patients with diabetes was caused by inflammation and counterregulatory hormones [9]. A 
study by Wu et al shows that the infection process caused an inflammatory storm. 
Furthermore, insulin resistance can occur. Thus, infection also inducing stress mechanism and 
sympathetic stimulation [10]. These support the hypothesis of inflammatory factor 
overexpression induces hyperglycemia. 
  Another mechanism of high blood sugar level was related to stress-induced. Zhou et al 
[6] and Yan Zhang et al [15] in their studies showed that high cortisol level induced by stress 
resulting in hyperglycemia by activating enzymes that involved in the gluconeogenesis process 
in the liver and inhibiting glucose uptake in peripheral tissues, such as the skeletal muscle. 
Glucocorticoid therapy in severe or critical COVID-19 patients may induce hyperglycemia by 
similar mechanism as stress-induced. However, glucocorticoid therapy is still used in many 
health facilities to manage the inflammation in COVID-19 patients.  
 
Mortality and Morbidity in Hyperglycemia induced by COVID-19 
 Hyperglycemia was an independent risk factor to critical condition and death in many 
infectious diseases, such as SARS and COVID-19 [17]. Dysregulation of immune system 
associated with hyperglycemia may contribute to high infection susceptibility and disease 
severity [18]. CT scans of patient with high fasting blood glucose showed more abnormalities 
rather than normoglycemic patients [8] Length of stay (LOS) was found to be slightly longer in 
patients with blood sugar level > 180 mg/dl than in patients with blood sugar level 140 – 180 
mg/dl and < 140 mg/dl, i.e. 12 days, 11.5 days, and 11.1 days, respecitively (p<0.011) [13]. 
 Mortality rate of COVID-19 patients with hyperglycemia was found to be high. A study 
by Carrasco et al [13] showed higher mortality rate in patient with blood sugar level on 
admission >180 mg/dl (41.1%)  than in patient with blood sugar level on admission 140 – 180 
mg/dl (33.0%) and <140 mg/dl (15.71%). Yang et al reported that death within 28 days in 
COVID-19 patients was associated with high level of fasting blood sugar. There were 27.4% 
subjects with fasting blood sugar level around 7.0 – 11.1 mmol/L and 21.3% subjects ≥ 11,1 
mmol/L [16]. Moreover, the blood sugar level is also an independent factor of any inpatient 
death cause. This showed that there were correlation between uncontrolled hyperglycemia 
with high mortality rate [19].  
 Hyperglycemia could disrupt the defensive capacity of airway epithelial, furthermore it 
will induce oxidative stress production. High level of oxidative stress and the reduction of 
heparan sulfate induced by hyperglycemia may result in thrombosis [9,12]. Elevation of 
glucose concentration in respiratory tract may results in local inflammation and worsen patient 
condition. Hyperglycemia in diabetic patient may impair the pulmonary function by decreasing 
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vital capacity and forced expiratory volume in one second (FEV1) due to microangiopathy 
development [8,12]. The immune system may also be harmed mainly innate immunity, hence 
the risk of being infected is increased in line hyperglycemia condition. Matrix 
metalloproteinases gene expression can be escalated in hyperglycemia condition resulting in 
more extensive spreading of the inflammation. In hypoxemic and hyperglycemic condition, in 
order to obtain adenosine triphosphatee (ATP), anaerobic glycolysis must occur. As a 
consequence, lactate and LDH level will increase. High lactate and LDH level were associated 
with high mortality in COVID-19 patients [8]. 
  A study by Zhang et al [12] showed that liver function impairment, elevation of LDH 
and IL-8 ratio were found more in COVID-19 patients with hyperglycemia without prior 
diabetes. Moreover, hyperglycemic condition in non-diabetic patients may aggravate the 
symptom of COVID-19 by increasing proinflammatory cytokines, such as interferon alpha (IFN-
α), interleukin 1 beta (IL-1β), interleukin 6 (IL-6), monocyte chemoattractant protein 1 (MCP1),  
interferon-γ-inducible protein 10 (IP-10), oxidative stresses, as well as disrupting inflammatory 
and anti-inflammatory cytokines balance [16]. As many as 20.6% subjects with COVID-19, 
hyperglycemic conditions, and no diabetes history were having severe symptoms and high 
mortality rate as showed in a study by Mamtani et al [5], while study by Coppelli et al [14]  was 
24% and Zhou et al [6] was 27.5%.  
  Diabetes is a common comorbid disease in COVID-19 patients and linked to severity of 
the symptom. Chronic inflammation and dysfunction of immune system may happen 
progressively in diabetic patients showed by the presence of abnormal T cell, hence cytokine 
storm occurs faster [12]. Immune paralysis, or the inability of the immune response to recover 
despite clearance of pathogens by antimicrobials taking a major part in COVID-19 patients with 
diabetes and associated with high mortality rate [15]. Another study showed that deaths in 
hospital caused by COVID-19 were found to be higher in patient with diabetes than in patient 
without any comorbidities [20]. Mortality rate in COVID-19 patients with diabetes caused by 
hyperglycemic condition was 21.3%, higher than control group which was only 9.5% [12]. 
Hyperglycemia in diabetes also linked to higher chance for patients to acquire acute 
respiratory distress syndrome (ARDS) (58%), acute cardiac injury events (38.7%), shock 
(40.3%), secondary infection (43.5%) and acute kidney injury (AKI) (16.1%) than patients 
without diabetes (p<0.05) [19]. 
  Patient with new-onset hyperglycemia, such as stress hyperglycemia and undiagnosed 
diabetes, had higher mortality rate in hospital than patient with history of diabetes or 
normoglycemia as shown in a study by Cakir et al [21]. This condition is linked to more 
gluconeogenesis and less glycogenolysis caused by the increase of counterregulatory hormone 
secretion. An autopsy of COVID-19 patient found Langerhans cell degeneration supports the 
statement [19]. Acute hyperglycemia occured in 22% of confirmed COVID-19 patients in 
hospital and 18.9% of them have been diagnosed with diabetes.19 Another study showed 50% 
confirmed COVID-19 patients had hyperglycemia and only 7% of them  had diabetes history 
[22]. 
 Hyperglycemia may worsen the severity of COVID-19 and cause critical condition in 
patients [23]. Study by Zhang et al [15] showed significant increment of patient risk having 
worse condition, for example mechanical ventilation usage, intensive care unit (ICU) 
admission, and death in group of patients with COVID-19 and hyperglycemia without history of 
diabetes (fasting blood sugar level ≥7.0 mmol/L, yet HbA1c level <6.5%) than in group of 
normoglycemic patients (OR 5.47; confidence interval 95% (CI), 1.51 – 19.82; p=0.010). 
Hyperglycemia increase the mortality risk in COVID-19 patients three times greater than 
normoglycemic patient (OR 2.822, 95% CI=1.587–5.019, p<0.001) [16]. Sardu et al [24] also 
showed 71% relative increase of mortality in group of patient with severe COVID-19 and 
hyperglycemia on admission (new-onset hyperglycemia without history of diabetes; plasma 
blood sugar level >7.77 mmol/L or 140 mg/dl) than in group of normoglycemic or non-diabetes 
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patient, within 18 days. Thus, insulin therapy in hyperglycemic patient has been proved to 
derease the severity of COVID-19 than no insulin therapy.  
 Yang et al [16] reported significant raise of emerging complication during 28 days of 
hospital stays (OR 2.61; 95% CI=1.64 – 4.41) in group of patients with COVID-19 and 
hyperglycemia without diabetes (blood sugar level 6.1 – 6.9 mmol/L) compared to 
normoglycemic patients. Meanwhile, Li et al [22] showed increment of death caused by 
COVID-19 in a group of hyperglycemic patients without diabetes (fasting blood sugar level 5.6 
– 6.9 mmol/L or HbA1c level 5.7 – 6.4%) compared to normoglycemic patients (fasting blood 
sugar level <5.6 mmol/L and HbA1c <5.7%) (HR 3.29; 95% CI=0.65-16.6). Coppelli et al [14] 
stated that mortality was found to be significantly higher in a group of COVID-19 patients with 
hyperglycemia and no diabetes history (defined as no history of diabetes and blood sugar level 
≥7.78 mmol/L on admission) compared to group of normoglycemic patients (blood glucose 
level <7.78 mmol/L  on admission) (39.4% vs 16.8%, respectively; HR 2.20; 95% CI=1.27 – 3.81; 
p=0.005) on 17 days observation. 
 The number of diabetic COVID-19 patients having high fasting blood sugar was found 
to be greater than non-diabetic patient, 82.3% versus 38.3%. This study also showed that 
diabetes patients had blood sugar levels in the range of 8.49 – 19.09 mmol/L, while patients 
without diabetes in the range of 5.67 – 7.95 mmol/L. Another parameter was used to compare 
COVID-19 patient with diabetes and without diabetes, for example differential white blood cell 
count, D-dimer level, albumin level, inflammatory markers (hsCRP, procalcitonin, ferritin, IL-2R, 
IL-6, and TNF- α). In patients with diabetes, absolute neutrophil count was higher compared to 
lymphocyte count, D-dimer and inflammatory markers level increased, and albumin level was 
lower than patients without diabetes [22]. 
 Hyperglycemia also can be found in COVID-19 patients during the hospital stay, even in 
patients without history of diabetes [10]. Hyperglycemia in non-diabetic patients may worsen 
the prognosis of COVID-19. The median of blood sugar level was observed to be high in 
patients whose condition was critical. (OR 2.39; 95% CI=1.41-4.07, p=0.001) [13]. Compared to 
hyperglycemic patients with diabetes, hyperglycemic patients without diabetes history had 
significantly higher mortality rate. In a study by Bode et al [23] showed that mortality rate was 
found to be very high in non-diabetic patients with uncontrolled hyperglycemia (41.7%) 
compared to diabetic patients (14.8%) (p<0.001). This finding is supported by study from 
Carrasco et al that showed mortality rate in non-diabetic COVID-19 patients with blood sugar 
level >180 mg/dl on admission was 43.3% [13]. 
 A study by Zhang et al [12] evaluated the association between hyperglycemia in 
confirmed COVID-19 patients with diabetes and without diabetes. The study divided subjects 
to three group: control group or first group (patients had no diabetes history and the fasting 
blood glucose level was <126 mg/dl), secondary hyperglycemia or second group (patients had 
no diabetes history and the HbA1c level <6.5%, but the fasting blood glucose level was ≥126 
mg/dl), and diabetes group or third group (patients had diabetes history, the HbA1c level 
≥6.5%, and the fasting blood sugar level was ≥126 mg/dl). Mortality rate of second and third 
group were significantly higher than the first group (21.3%, 14.3%, dan 9.5%, repectively; 
p<0.05). After the confounding factors were controlled, the odd ratio between the second 
group and third group versus first group were 5.47 (95% CI=1.56-19.82) and 2.61 (CI 95%=0.86-
7.88), respectively. This data showed that hyperglycemia is associated with bad prognosis and 
high mortality rate in COVID-19 patients. 
 It has been mentioned that hyperglycemia in COVID-19 leads to a more severe 
prognosis (intensive care unit care necessity, mechanical ventilation usage, and hemodynamic 
instability) and higher mortality rate either patients have diabetes or not. In other words, 
blood glucose level can be used as a predictor for COVID-19 patients outcome [12,13]. 
Hyperglycemia also has been used as independent factor to predict the severity in viral 
infection, such as influenza A (H1N1) in 2009, MERS-CoV, and SARS-CoV [17,25,26]. Based on 
Mamtani et al [5] study, random blood glucose level ≥10 mmol/L in more than two tests or 
Theodore, D.T., et al., Hyperglycemia Induced by COVID-19 with and without Present Diabetes: A Systematic Review, KELUWIH: 
Jurnal Kesehatan dan Kedokteran, Vol.2(2), 64-74, Juni 2021. 
https://doi.org/10.24123/kesdok.v2i2.4431 
 
                                       http://journal.ubaya.ac.id/index.php/kesdok |  e-ISSN: 2715-6419     72 
fasting blood glucose level ≥7 mmol/L in COVID-19 patients lead to worse prognosis. While 
another study by Liu et al [4] showed more severe COVID-19 condition were found in patients 
with fasting blood glucose level ≥ 6.50 mmol / L. For every 2 mmol/L or 36 mg/dL the fasting 
blood glucose rises, the outcome will be more severe [27]. 
 Blood sugar levels may fluctuate at different time. A study by Yang et al [16] showed 
that sample collection time affect the level of blood sugar. Blood glucose level test on 
admission could predict the mortality rate in COVID-19 patient, higher blood glucose level 
resulting in higher mortality risks. The controlled blood glucose levels in hyperglycemic COVID-
19 patients either with or without a history of diabetes showed a decrease in mortality and 
severity. We recommend every healthcare facilities to test blood glucose level periodically for 
COVID-19 patients on admission and daily during the hospital stay. The earlier it is detected, 
the earlier patients are treated. As a consequence, a better outcome in COVID-19 patients. 
 
CONCLUSION 
 Hyperglycemia is associated with COVID-19 either in diabetic or non-diabetic patients 
and it increases the severity in both conditions. High mortality and morbidity were found in 
hyperglicemic COVID-19 patients. Therefore, blood sugar level could predict the outcome of 
COVID-19 patient. Blood sugar level test, especially fasting blood sugar level and random blood 
sugar level can be used to detect hyperglycemia as an indicator for COVID-19 severity.  
Monitoring on blood sugar level should be done periodically on COVID-19 patients despite the 
symptoms are absent or not severe. Early detection of hyperglycemia leads clinicians to the 
early and right management for the patients. As a result, mortality rate due to COVID-19 
decreases. We suggest periodic blood sugar test as screening for hyperglycemia in hospitalized 
COVID-19 patients since COVID-19 can induce hyperglycemia in both diabetic patients and 
non-diabetic patients. 
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